You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Baxter
Dow
Medtronic

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

RITUXAN HYCELA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RITUXAN HYCELA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
Academic and Community Cancer Research UnitedPhase 2
National Cancer Institute (NCI)Phase 2

See all RITUXAN HYCELA clinical trials

Recent Litigation for RITUXAN HYCELA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
ABBVIE INC. v. DR. REDDY'S LABORATORIES, INC.2020-07-22
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28
Pharmacyclics LLC v. Alvogen Pine Brook, LLC2020-03-20

See all RITUXAN HYCELA litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all RITUXAN HYCELA litigation

Patent Text Search: US Patents for RITUXAN HYCELA

These patents were identified by searching patent claims

Supplementary Protection Certificates for RITUXAN HYCELA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
LUC00044 Luxembourg   Start Trial PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703
CA 2017 00053 Denmark   Start Trial PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKesson
Medtronic
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.